Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)

Next Previous
Search
Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemigatinib (Primary) ; Cisplatin; Docetaxel; Gemcitabine; Pembrolizumab; Retifanlimab; Trastuzumab
  • Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Endometrial cancer; Gastric cancer; Multiple myeloma; Myeloproliferative disorders; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Acronyms FIGHT-101
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 12 Dec 2022 Status changed from completed to discontinued.
    • 01 Apr 2022 Results of population pharmacokinetics model from three trials (phase 1 dose-escalation/dose-expansion study, a phase 1 Japanese PK bridging study, and a phase 2 cholangiocarcinoma study.) published in the Clinical Pharmacology in Drug Development
    • 14 Feb 2022 Results published in the Annals of Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top